The COlchicine HypERtENsion Trial

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511391-32-00

Acronym

COHERENT

Enrollment

150

Registered

2024-07-10

Start date

2021-08-10

Completion date

2026-01-09

Last updated

2024-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular disease, Hypertension

Brief summary

Change in carotid-femoral pulse wave velocity at 6 months

Detailed description

Change in office-measured systolic blood pressure at 6 months, Change in office-measured diastolic blood pressure at 6 months, Change in LV mass index assessed by echocardiography at 6 months, Change in hs-CRP at 6 months, Change in hs-TnI at 6 months

Interventions

DRUGPlacebo will be identical in appearance and contain the following ingredients: lactosemonohydrate

DRUGpotato starch

DRUGspiritus gelatinae 5%

DRUGmagnesium stearate

DRUGtalcum.

DRUGColchicin "Tiofarma"

DRUGtabletter

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in carotid-femoral pulse wave velocity at 6 months	—

Secondary

Measure	Time frame
Change in office-measured systolic blood pressure at 6 months, Change in office-measured diastolic blood pressure at 6 months, Change in LV mass index assessed by echocardiography at 6 months, Change in hs-CRP at 6 months, Change in hs-TnI at 6 months	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026